Data from this study suggests that methotrexate, when administered to JIA FLS in culture, can mimic the behavior of a BMP4 inhibitor and consequently preclude these cells from contributing to joint growth disturbances associated with JIA. Here, BMP4 is linked to juvenile idiopathic arthritis.